PNA Monomers

At ASM we are involved in the synthesis of PNA monomers since the foundation of the company in 2005. Our product portfolio consists of standard Fmoc-PNA monomers and Boc-PNA monomers, which can be ordered in quantities up to 50g from stock, and a large variety of  backbone- and base-modified peptide nucleic acids.

Within these 15 years, we were able to gain tremendous experience in the synthesis, modification and purification of peptide nucleic acids.

PNAs, short for Peptide Nucleic Acids, were designed in a computer model in the 1990s by Peter E. Nielsen of the University of Copenhagen as reagents that bind sequence specific to double stranded DNA[1]. To ensure nuclease stability and cell membrane permeability, the deoxyribose phosphate backbone of DNA has been exchanged by a achiral peptide backbone. The nature of that backbone arose from a computer model which indicated that (2-aminoethyl)glycine units and nucleobase attachments via methylene carbonyl linkers could be used to mimic a DNA backbone[2]. The subsequent synthesis of PNAs employing this unique feature proved the inventors* right and since then, PNAs, which are synthesized from the commercially available PNA monomers, became an excellent tool for artificial oligonucleotide mimetics with higher metabolic stability and formation of more stable duplexes and triplexes with DNA and RNA than either of them. These advantageous characteristics made PNAs valuable compounds as antisense and antigen agents, among other applications[3]. Further applications for PNAs are actively researched in academia, and commercial products using PNAs are in development.

Fmoc PNA monomers

Boc PNA monomers

Modified PNA monomers

Building blocks and reagents

* License Statement: PNA Monomers are made and sold pursuant to license under one or more of US Patents Nos. US 5,773,571, US 6,133,444, US 6,172,226, US 6,395,474, US 6,414,112, US 6,613,873, US 6,710,163 and US 6,713,602, or corresponding patent claims outside the US and are provided only for use in academic and commercial research and not for any commercial purposes. Information about licenses for commercial use of PNA Monomers is available from the PNA Inventor Group. E-mail:

[1] Nielsen, P. E.; Egholm, M.; Berg, R. H.; Buchardt, Science 1991, 254, 1497.
[2] Egholm, M.; Buchardt, 0.; Nielsen, P. E.; Berg, R. H. J. Am. Chem. Soc. 1992, 114, 1895.
[3] J. Saarbach, P. M. Sabale, N. Winssinger, Curr. Opin. Chem. Biol. 2019, 52, 112–124.